Objectives: A deep learning (DL) model using image data from pretreatment [ 18 F]fluorodeoxyglucose ([ 18 F] FDG)-PET or computed tomography (CT) augmented with a novel imaging augmentation approach was developed for the early prediction of distant metastases in patients with locally advanced uterine cervical cancer.
Methods: This study used baseline [18F]FDG-PET/CT images of newly diagnosed uterine cervical cancer patients. Data from 186 to 25 patients were analyzed for training and validation cohort, respectively. All patients received chemoradiotherapy (CRT) and follow-up. PET and CT images were augmented by using three-dimensional techniques. The proposed model employed DL to predict distant metastases. Receiver operating characteristic (ROC) curve analysis was performed to measure the model's predictive performance.
Results: The area under the ROC curves of the training and validation cohorts were 0.818 and 0.830 for predicting distant metastasis, respectively. In the training cohort, the sensitivity, specificity, and accuracy were 80.0%, 78.0%, and 78.5%, whereas, the sensitivity, specificity, and accuracy for distant failure were 73.3%, 75.5%, and 75.2% in the validation cohort, respectively.
Conclusion: Through the use of baseline [ 18 F]FDG-PET/CT images, the proposed DL model can predict the development of distant metastases for patients with locally advanced uterine cervical cancer treatment by CRT. External validation must be conducted to determine the model's predictive performance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MNM.0000000000001799 | DOI Listing |
PLoS One
December 2024
Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.
Purpose: To reveal problems of magnetic resonance imaging (MRI) for diagnosing gastric-type mucin-positive (GMPLs) and gastric-type mucin-negative (GMNLs) cervical lesions.
Methods: We selected 172 patients suspected to have lobular endocervical glandular hyperplasia; their pelvic MR images were categorised into the training (n = 132) and validation (n = 40) groups. The images of the validation group were read twice by three pairs of six readers to reveal the accuracy, area under the curve (AUC), and intraclass correlation coefficient (ICC).
PLoS One
January 2025
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan.
The incidence and mortality rates of cervical cancer are increasing among young Japanese women. In November 2021, the Japanese Ministry of Health, Labour, and Welfare reinstated the active recommendation of the human papillomavirus (HPV) vaccine, after it had been suspended in June 2013 due to reports of adverse reactions. However, vaccine hesitancy is prevalent in the younger generation in Japan.
View Article and Find Full Text PDFSci Data
January 2025
Department of Health Management, Harbin Medical University, Harbin, 150081, China.
Accurate detection of abnormal cervical cells in cervical cancer screening increases the chances of timely treatment. The vigorous development of deep learning methods has established a new ecosystem for cervical cancer screening, which has been proven to effectively improve efficiency and accuracy of cell detection in many studies. Although many contributing studies have been conducted, limited public datasets and time-consuming collection efforts may hinder the generalization performance of those advanced models and restrict further research.
View Article and Find Full Text PDFBMJ Open
January 2025
Global Health Working Group, Institute of Medical Epidemiology, Biometrics and Informatics, Martin Luther University Halle Wittenberg, Halle, Germany.
Introduction: The follow-up adherence after treatment for a positive screening test is critical for preventing the development of screen-detected abnormalities in cervical cancer. Yet, this poses a major challenge in developing countries like Ethiopia, emphasising the urgency for intervention strategies. Our trial aims to assess which strategies would be effective in improving adherence to follow-up after suspicious cervical lesion treatment in Ethiopia.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Department of gynecological oncology, Oslo University Hospital, Oslo, Norway
Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!